Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA requests comments on CFSAN program priorities for FY 2004, including "new program areas or activities that should be added as high priority" for the year as well as on "which 'B-list' activities should be elevated to the 'A-list' for completion in FY 2004." In 1June 5 Federal Register notice, agency notes it expects "considerable continuity and follow-through between the 2003 and 2004 work plans." For example, FDA notes "new initiatives aimed at increasing the security of our country's food supply...will continue to be a high priority in FY 2004." Comments are due Aug. 4...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel